Draft interdisciplinary guidelines for diagnosis, methods for estimation of the degree of activity, for evaluation of therapeutic efficacy, and for use of biological agents in patients with concomitant immunoinflammatory diseases (psoriasis, psoriatic arthritis, Crohn's disease)

Due to that one patient may be at high risk for developing several immunoinflammatory diseases (psoriasis, psoriatic arthritis (PsA), and Crohn's disease (CD)), their early diagnosis and adequate therapy are extremely relevant. The Interdisciplinary Working Group that includes experts in rheumatology, gastroenterology and dermatology has developed draft guidelines for early diagnosis, methods for activity assessments and for indications for the use of biological agents in patients with concomitant immunoinflammatory diseases (psoriasis, PsA, and CD). In accordance with the decision adopted by the Council of Experts and with the results of a discussion with experts from different regions of the Russian Federation, further steps will be undertaken to validate the guidelines.

1. Kavanaugh A, Helliwell P, Ritchlin C. Psoriatic arthritis and burden of disease: patient perspectives from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey. Rheumatol Ther. 2016 Jun;3(1):91-102. doi: 10.1007/s40744-0160029-z. Epub 2016 Feb 29.

2. Batkaeva NV, Korotaeva TV, Batkaev EA. Prevalence of psoriatic arthritis and comorbidities in patients with severe psoriasis: Data of a retrospective analysis of a hospital cohort. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2017;11(1):19-22. (In Russ.). doi: 10.14412/1996-70122017-1-19-22.

3. Davidovici BB, Sattar N, Prinz J, et al. Psoriasis and systemic infammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010 Jul;130(7):1785-96. doi: 10.1038/jid.2010.103. Epub 2010 May 6.

4. Ogdie A, Schwartzman S, Husni ME. Recognizing and managing comorbidities in psoriatic arthritis. Curr Opin Rheumatol. 2015 Mar;27(2):118-26. doi: 10.1097/BOR.0000000000000152.

5. Oliveira MF, Rocha BO, Duarte GV. Psoriasis: classical and emerging comorbidities. An Bras Dermatol. 2015 Jan-Feb;90(1):9-20. doi: 10.1590/abd1806-4841.20153038.

6. Benson J, Peritt D, Scallon B, et al. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin23 for treatment of immune-mediated disorders. MAbs. 2011 Nov-Dec;3(6):535-45. doi: 10.4161/mabs.3.6.17815. Epub 2011 Nov 1

7. Puig L, Carrascosa JM, Carretero G, et al; Spanish Psoriasis Group of the Spanish. Academy of Dermatology and Venereology. Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: on efficacy and choice of treatment. Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Actas Dermosifiliogr. 2013 Oct;104(8):694-709. doi: 10.1016/j.adengl.2013.04.013. Epub 2013 Sep 7.

8. Canadian Dermatology Association. Canadian guidelines for the management of plaque psoriasis. www.dermatology.ca/wp-content/uploads/2012/01/cdnpsoriasisguidelines.pdf

9. Armstrong AW, Brezinski EA, Follansbee MR, et al. Effects of biologic agents and other diseasemodifying antirheumatic drugs on cardiovascular outcomes in psoriasis and psoriatic arthritis: a systematic review. Curr Pharm Des.2014;20(4): 500-12.

10. Shah K, Paris M, Mellars L, et al. Realworld burden of comorbidities in US patients with psoriatic arthritis. RMD Open. 2017 Dec 28;3(2):e000588. doi: 10.1136/rmdopen-2017000588. eCollection 2017.

11. Coates LC, Gossec L, Ramiro S, et al. New GRAPPA and EULAR recommendations for the management of psoriatic arthritis. Rheumatology (Oxford). 2017 Aug 1;56(8):12511253. doi: 10.1093/rheumatology/kew390.

12. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005 Mar;64 Suppl 2:ii14-7

13. Theander E, Husmark T, Alenius GM, et al. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA). Ann Rheum Dis. 2014 Feb;73(2):40713. doi: 10.1136/annrheumdis-2012-201972. Epub 2013 Jan 25.

14. Egeberg A, Mallbris L, Warren RB, et al. Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study. Br J Dermatol. 2016 Sep;175(3):487-92. doi: 10.1111/bjd.14528. Epub 2016 Jun 20.

15. Loftus E, Augustin M, Bissonnette R, et al. P626 Prevalence of inflammatory bowel disease amongst patients with psoriasis and incidence of serious infections in this subset: results from the PSOLAR Registry. Poster Presentation at European Crohn’s and Colitis Annual Meeting 2016 https://www.ecco-ibd.eu/publications/congress-abstract-s/abstracts-2016/item/p626prevalence-of-inflammatory-bowel-diseaseamongstpatients-with-psoriasis-and-incidenceof-serious-infections-in-this-subsetresultsfrom-the-psolar-registry.html

16. Vavricka SR, Brun L, Ballabeni P, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol. 2011 Jan;106(1):110-9. doi: 10.1038/ajg.2010.343. Epub 2010 Aug 31.

17. Cohen R, Robinson DJ, Paramore C, et al. Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001-2002. Inflamm Bowel Dis. 2008 Jun;14(6):738-43. doi: 10.1002/ibd.20406.

18. Coates LC, Moverley AR, McParland L, et al. Effect of tight control inflammation in early psoriatic arthritis (TICOPA): a UK multicenter, open-label, randomized controlled trial. Lancet. 2015 Dec 19;386(10012):2489-98. doi: 10.1016/S0140-6736(15)00347-5. Epub 2015 Oct 1.

19. Coates LC, Helliwell PS. Treating to target in psoriatic arthritis: how to implement in clinical practice. Ann Rheum Dis. 2016 Apr;75(4): 640-3. doi: 10.1136/annrheumdis-2015-208617. Epub 2015 Dec 15.

20. Gulliver W, Lynde C, Dutz JP, et al. Think beyond the skin: 2014 Canadian expert opinion paper on treating to target in plaque psoriasis. J Cutan Med Surg. 2015 Jan-Feb;19(1):22-7. doi: 10.2310/7750.2014.13151. Epub 2015 Jan 1.

21. Clinical guidelines for Psoriasis 2016 http://cr.rosminzdrav.ru/schema.html?id=866#/text

22. Carretero G, Puig L, Carrascosa JM, et al. Redefining the therapeutic objective in psoriatic patients candidates for biological therapy. J Dermatolog Treat. 2018 Jun;29(4):334-346. doi: 10.1080/09546634.2017.1395794. Epub 2017 Nov 21.

23. Smolen J, Schols M, Braun J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018 Jan;77(1):3-17. doi: 10.1136/annrheumdis-2017211734. Epub 2017 Jul 6.

24. Gossec L, McGonagle D, Korotaeva T, et al. Minimal Disease Activity as a Treatment Target in Psoriatic Arthritis: A Review of the Literature. J Rheumatol. 2018 Jan;45(1):6-13. doi: 10.3899/jrheum.170449. Epub 2017 Nov 15.

25. Loginova EYu, Korotaeva TV, Smirnov AV, et al. Achievement of minimal disease activity and progression of radiographic changes in early psoriatic arthritis one year after initiation of treatment in «treat to target» strategy (preliminary results of the REMARKA study). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2017;55 (6):610-5. (In Russ.). doi: 10.14412/1995-4484-2017-610-615

26. Allen PB, Olivera P, Emery P, et al. Review article: moving towards common therapeutic goals in Crohn’s disease and rheumatoid arthritis. Aliment Pharmacol Ther. 2017 Apr;45(8): 1058-1072. doi: 10.1111/apt.13995. Epub 2017 Mar 1.

27. Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-toTarget. Am J Gastroenterol. 2015 Sep;110(9): 1324-38. doi: 10.1038/ajg.2015.233. Epub 2015 Aug 25.

28. Colombel J, Narula N, Peyrin-Biroulet L. Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases. Gastroenterology. 2017 Feb;152(2):351-361.e5. doi: 10.1053/j.gastro.2016.09.046. Epub 2016 Oct 5.

29. Chandran V, Gottlieb A, Cook RJ, et al. International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis. Arthritis Rheum. 2009 Sep 15;61(9):1235-42. doi: 10.1002/art.24562.

30. Walsh JA, McFadden M, Woodcock J, et al. Product of the Physician Global Assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort. J Am Acad Dermatol. 2013 Dec;69(6):931-7. doi: 10.1016/j.jaad.2013.07.040. Epub 2013 Sep 17.

31. Gladman D, Poulin Y, Adams K, et al. Treating Psoriasis and Psoriatic Arthritis: Position Paper on Applying the Treat-to-target Concept to Canadian Daily Practice. J Rheumatol. 2017 Apr;44(4):519-534. doi: 10.3899/jrheum.161473.

32. Chandran V, Maharaj A. Assessing disease activity in psoriasis and psoriatic arthritis: impact on management and therapy. Expert Rev Clin Immunol. 2016;12(5):573-82. doi: 10.1586/1744666X.2016.1146133. Epub 2016 Feb 19.

33. Gaidukova IZ, Rebrov AP, Korotaeva TV, et al. Remission in axial spondyloarthritis: definition and evaluation tools (recommendations of the spondyloarthritis study group of experts, all-russian public organization «The Association of Rheumatology of Russia»). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2018; 56(1):10-5. (In Russ.). doi: 10.14412/19954484-2018-10-14.

34. Ivashkin VT, Shelygin YuA, Khalif IL, et al. Clinical guidelines of the Russian gastroenterological Association and the Association of coloproctologists of Russia for the diagnosis and treatment of Crohn's disease. Koloproktologiya. 2017;(2): 7-29. (In Russ.).

35. Kerdel А, Zaiac M. An evolution in switching therapy for psoriasis patients who fail to meet treatment goals. Dermatol Ther. 2015 NovDec;28(6):390-403. doi: 10.1111/dth.12267. Epub 2015 Aug 10.

36. Feagan BG, Sandborn WJ, Gasink C, et al.; UNITI-IM-UNITI Study Group. Ustekinumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2016 Nov 17;375(20):1946-1960.

37. Amin M., No DJ, Egeberg A, Wu JJ. Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say? Am J Clin Dermatol. 2018 Feb; 19(1):1-13. doi: 10.1007/s40257-017-0328-3.

38. Instructions for use of the drug for medical use StelaraR.

39. Kim BS, Lee WK, Pak K, et al. Ustekinumab treatment is associated with decreased systemic and vascular inflammation in patients with moderate to severe psoriasis: Feasibility study using 18F-fluorodeoxyglucose positron emission tomography-computed tomography. J Am Acad Dermatol. 2018 Mar 17. pii: S0190-9622(18)30461-4. doi: 10.1016/ j.jaad.2018.03.011. [Epub ahead of print].

40. No DJ, Inkeles MS, Amin M, Wu JJ. Drug survival of biologic treatments in psoriasis: a systematic review. J Dermatolog Treat. 2017 Nov 10:1-7. doi: 10.1080/09546634.2017.1398393. [Epub ahead of print].

41. Egeberg A. Safety, efficacy and drug survival of biologics and biosimilars for moderate-tosevere plaque psoriasis. Br J Dermatol. 2018 Feb;178(2):509-519. doi: 10.1111/bjd.16102. Epub 2018 Jan 9

42. Daperno M , D'Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc. 2004 Oct;60(4):505-12.